Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

– Breadth of Alto's pipeline and Precision Psychiatry Platform will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical

BusinesswireMay 9 20:05

Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape

Recently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with

BenzingaApr 24 02:55

Alto Neuroscience Schizophrenia Treatment Shows Good Phase 1 Results

Seeking AlphaApr 24 01:21

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated with PDE4

BusinesswireApr 23 20:05

Alto Neuroscience Has Initiated Phase 2 Study Of ALTO-203 In Major Depressive Disorder; Alto Expects To Report Topline Data From This Study In 1H Of 2025

Alto Neuroscience Has Initiated Phase 2 Study Of ALTO-203 In Major Depressive Disorder; Alto Expects To Report Topline Data From This Study In 1H Of 2025

BenzingaApr 3 20:10

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients With Major Depressive Disorder

Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder (MDD) and higher levels of anhedonia ALTO-203 demonstrated a

BusinesswireApr 3 20:05